Categories AlphaGraphs, Earnings, Industrials
BA Earnings: Highlights of Boeing’s Q4 2022 financial results
The Boeing Company (NYSE: BA) on Wednesday announced financial results for the fourth of 2022, reporting a sharply narrower net loss, on an adjusted basis. Revenues grew 35%.
Core earnings, adjusted for special items, narrowed sharply to $1.75 per share in the December quarter from $7.69 per share in the year-ago quarter. On an unadjusted basis, the net loss was $663 million or $1.06 per share, compared to a loss of $4.16 billion or $7.02 per share in the fourth quarter of 2021.
The bottom line benefitted from a 35% increase in revenues to $19.9 billion. During the quarter, the company generated $3.5 billion in operating cash flow and $3.1 billion in free cash flow.
“Demand across our portfolio is strong, and we remain focused on driving stability in our operations and within the supply chain to meet our commitments in 2023 and beyond. We are investing in our business, innovating and prioritizing safety, quality, and transparency in all that we do,” said Boeing’s CEO Dave Calhoun.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training